ConductScience.org, home

Paper38142147

The potential of mRNA vaccines in cancer nanomedicine and immunotherapy.

Pan S and 4 others. Trends Immunol, 2024. Cited by 28 papers, by iCite.

Cite this record

ConductScience Library. The potential of mRNA vaccines in cancer nanomedicine and immunotherapy. Papers, record 38142147. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38142147

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The potential of mRNA vaccines in cancer nanomedicine and immunotherapy.
PubMed
Journal
Trends Immunol
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
28
iCite
Relative citation ratio, by iCite
3.24, provisional
iCite
Revised in PubMed
2024-03-21
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Pan SShulin
2Fan RRangrang
3Han BBo
4Tong AAiping
5Guo GGang

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
NeoplasmsMajor topic
Cancer VaccinesMajor topic
Humans
Nanomedicine
mRNA Vaccines
Immunotherapy

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
31971308, 82102767 AND U1903211National Natural Sciences Foundation of ChinaPubMed
2023AB047Science and Technology Planning Project of Shihezi UniversityPubMed
2019ZX09301-147National S&T Major ProjectPubMed
2022YFS0007Sichuan Science and Technology ProgramPubMed

Source PubMed

Download CSV of grants

Cited by14

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.

PMIDTitleJournalYearIn PapersSource
42871871Oxygen-generating cryogel vaccines help overcome tumor antigen tolerance and induce durable antitumor immunity in prostate cancer.Cell Biomater2026https://conductscience.org/library/papers/42871871PubMed
42646699Advances in Therapeutic Melanoma Vaccines (2010-2025).Vaccines (Basel)2026https://conductscience.org/library/papers/42646699PubMed
42482783mRNA cancer vaccines: delivery strategies, immune modulation, and clinical translation.Front Pharmacol2026https://conductscience.org/library/papers/42482783PubMed
41909509Nanomaterial-driven modulation of lipid metabolism: Novel strategies toward precision obesity treatment.Bioact Mater2026https://conductscience.org/library/papers/41909509PubMed
41492458Targeted reduction-responsive nanovehicles for photodynamic therapy-primed immunotherapy in melanoma.J Pharm Anal2025https://conductscience.org/library/papers/41492458PubMed
41377933mRNA Cancer Vaccines: From Pandemic Paradigm to Personalized Oncology Therapeutics.Cancer Innov2025https://conductscience.org/library/papers/41377933PubMed
41366793Convergence of mRNA technology and chimeric antigen receptor therapy: targeted technology optimizing targeted therapy.J Transl Med2025https://conductscience.org/library/papers/41366793PubMed
41179708mRNA Vaccines: Current Applications and Future Directions.MedComm (2020)2025https://conductscience.org/library/papers/41179708PubMed
40352591Expanding horizons of cancer immunotherapy: hopes and hurdles.Front Oncol2025https://conductscience.org/library/papers/40352591PubMed
40137165Nanomedicines Targeting Metabolic Pathways in the Tumor Microenvironment: Future Perspectives and the Role of AI.Metabolites2025https://conductscience.org/library/papers/40137165PubMed
39762875mRNA vaccines in the context of cancer treatment: from concept to application.J Transl Med2025https://conductscience.org/library/papers/39762875PubMed
39543114Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications.Signal Transduct Target Ther2024https://conductscience.org/library/papers/39543114PubMed
39534380Nasal mRNA Nanovaccine with Key Activators of Dendritic and MAIT Cells for Effective Against Lung Tumor Metastasis in Mice Model.Int J Nanomedicine2024https://conductscience.org/library/papers/39534380PubMed
39242807A translational framework to DELIVER nanomedicines to the clinic.Nat Nanotechnol2024https://conductscience.org/library/papers/39242807PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38142147

GET https://conductscience.org/api/papers/v1/38142147/authors